Loading...
Indian Pharmaceutical Exporter · Other Specialist · $2.8M Total Trade · DGFT Verified
Premium Serums AND Vaccines Private Limited is an Indian pharmaceutical exporter with a total trade value of $2.8M across 2 products in 1 therapeutic categories. Based on 102 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Serum ($1.4M), Antitoxin ($1.4M), .
Premium Serums and Vaccines Private Limited, established on January 29, 2009, is a private limited company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24110MH2009PTC189968. Its authorized and paid-up capital stands at ₹2.00 crore each. The registered office is located at 406, B Wing, Highway Rose Co-Op Hsg Society 92, Dixit Road Extension, Vile Parle (East), Mumbai, Maharashtra, 400057.
As of April 7, 2024, Premium Serums and Vaccines employed 82 professionals. The company's leadership comprises Directors Shyam Bhalchandra Dhawan and Girish Nathuram Kolwankar. In the fiscal year ending March 31, 2023, the company reported a 48.43% increase in total revenue, a 27.35% rise in profit, and a significant 386.65% growth in net worth.
Premium Serums AND Vaccines Private Limited operates across 1 therapeutic categories, with Other (100.0%), representing the largest segments by export value. The portfolio is concentrated — the top 5 products account for 100% of total exports.
Other
2 products · 100.0% · $2.8M
Premium Serums AND Vaccines Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.
| # | Product | Category | Export Value | Shipments | Market Share | Rank |
|---|---|---|---|---|---|---|
| 1 | Serum | Other | $1.4M | 31 | 5.3% |
Headquarters, ownership, manufacturing facilities, and key leadership
Premium Serums and Vaccines Private Limited, established on January 29, 2009, is a private limited company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24110MH2009PTC189968. Its authorized and paid-up capital stands at ₹2.00 crore each. The registered office is located at 406, B Wing, Highway Rose Co-Op Hsg Society 92, Dixit Road Extension, Vile Parle (East), Mumbai, Maharashtra, 400057.
As of April 7, 2024, Premium Serums and Vaccines employed 82 professionals. The company's leadership comprises Directors Shyam Bhalchandra Dhawan and Girish Nathuram Kolwankar. In the fiscal year ending March 31, 2023, the company reported a 48.43% increase in total revenue, a 27.35% rise in profit, and a significant 386.65% growth in net worth.
Premium Serums and Vaccines operates manufacturing facilities in Pune, Maharashtra, and Narayangaon, Maharashtra. The Pune facility is situated at Gate No. 354-1, 354-2, At/Po, Pune, Maharashtra, 410504. The Narayangaon facility is located in the Pune district. These facilities specialize in the production of equine immunoglobulin products, including antivenoms, antitoxins, serums, and vaccines.
| 3 |
| 2 | Antitoxin | Other | $1.4M | 71 | 10.1% | 2 |
Premium Serums AND Vaccines Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $2.8M. The top category is Other (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.
Shipment-level records, pricing & buyer contacts for Premium Serums AND Vaccines Private Limited.
Request DemoThe company's leadership includes Directors Shyam Bhalchandra Dhawan and Girish Nathuram Kolwankar. Specific roles such as CEO, MD, and CFO are not publicly disclosed. The company employs a team of 82 professionals as of April 7, 2024.
Regulated market presence, emerging market penetration, and geographic strategy
Premium Serums and Vaccines Private Limited's export data indicates a total export value of $2.8 million USD across 102 shipments, with products spanning one therapeutic category. The top two products, Serum and Antitoxin, each contributed $1.4 million USD, accounting for 5.3% and 10.1% market share, respectively. The company's portfolio is highly concentrated, with the top five products comprising 100% of exports. Specific regulatory approvals in the US, EU, UK, Australia, and Japan are not publicly disclosed.
The company's export data does not specify its presence in African, Latin American, or Southeast Asian markets. Additionally, there is no publicly available information regarding WHO prequalification status, which is essential for accessing certain international markets.
Premium Serums and Vaccines Private Limited's export data indicates a highly concentrated portfolio, with the top five products comprising 100% of exports. This suggests a focused geographic strategy, potentially limiting exposure to market diversification risks. However, the lack of detailed information on geographic diversification and market penetration strategies makes it challenging to assess the company's overall geographic strategy comprehensively.
FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record
Specific information regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history for Premium Serums and Vaccines Private Limited is not publicly available. The company's export data does not provide insights into its regulatory standing with the FDA.
There is no publicly available information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status for Premium Serums and Vaccines Private Limited. These certifications are crucial for market access in various international regions.
Specific details about the company's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data does not provide insights into its regulatory standing within India.
There is no publicly available information regarding Form 483 observations, warning letters, or import alerts associated with Premium Serums and Vaccines Private Limited. The company's export data does not indicate any recent regulatory actions or compliance issues.
Market share comparison, key differentiators, and strategic analysis
Premium Serums and Vaccines Private Limited operates in the equine immunoglobulin product segment, competing with other manufacturers in the antivenom, antitoxin, serum, and vaccine markets. Specific market share comparisons and head-to-head analyses are not publicly available. The company's export data indicates a highly concentrated product portfolio, which may impact its competitive positioning.
The company's focus on equine immunoglobulin products, including antivenoms, antitoxins, serums, and vaccines, positions it as a specialized manufacturer in this niche segment. However, the lack of detailed information on product innovations, quality certifications, and unique selling propositions makes it challenging to identify specific competitive advantages.
Premium Serums and Vaccines Private Limited's export data indicates a highly concentrated product portfolio, with the top five products comprising 100% of exports. This suggests a focused strategic direction, potentially limiting exposure to market diversification risks. However, the lack of detailed information on the company's strategic initiatives, such as expansion into generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, makes it challenging to assess its future outlook comprehensively.
Track record assessment, certifications to verify, and pre-order checks
The company's export data indicates a total export value of $2.8 million USD across 102 shipments, with products spanning one therapeutic category. The top two products, Serum and Antitoxin, each contributed $1.4 million USD, accounting for 5.3% and 10.1% market share, respectively. The company's portfolio is highly concentrated, with the top five products comprising 100% of exports. Specific information regarding the company's track record, export volume consistency, and reliability indicators is not publicly available.
Importers should verify the following certifications to ensure product quality and regulatory compliance:
When considering a partnership or procurement from Premium Serums and Vaccines Private Limited, importers should undertake the following verification steps:
Red flags to watch for include a lack of transparency in regulatory approvals, absence of quality certifications, financial instability, limited product diversity, and unreliable supply chain practices.
Recommended pre-order checks involve verifying the company's compliance with import regulations, confirming the authenticity of certifications, and conducting a thorough assessment of product quality and safety standards.
Premium Serums AND Vaccines Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Serum ($1.4M), Antitoxin ($1.4M). Total export value is $2.8M.
Premium Serums AND Vaccines Private Limited's total pharmaceutical export value is $2.8M, based on 102 verified shipments recorded in Indian Customs (DGFT) data.
Premium Serums AND Vaccines Private Limited exports across 1 therapeutic categories. The largest are Other (100.0%, 2 products).
Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify manufacturer licensing, GMP certification, and export registration with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2 Products Tracked
1 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.